Compare Amgen, Inc. (AMGN) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Vanguard Ultra Short Bond ETF — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Vanguard Ultra Short Bond ETF trades at $49.65. The key difference: Amgen, Inc. pays a 2.77% dividend while Vanguard Ultra Short Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | VUSB | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.16 | $50.03 |
52-Week Low | $271.18 | $49.60 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
VUSB trades at $49.66 with minimal daily movement, showing a slight 0.01% gain. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators are neutral. The ETF offers a yield of approximately 4.35% and is positioned as a cash alternative amid a non-inverted yield curve, with recent dividends paid in mid-2026.
The outlook for VUSB is cautious due to bearish technicals and potential Fed rate increases in 2026, which could impact short-term bonds. Risks include interest rate sensitivity and credit/duration exposure, but the ETF remains a viable option for investors seeking yield above money-market funds with moderate risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
